title: [Prevention of reinfarction with 100 mg or 30 mg ASS daily?].
abstract: The prevention of heart infarction with 100 mg aspirin is common practice in Germany, in spite of the fact that it is based on only two small studies, the results of which are not generalized. Over 14 years, several experimental and clinical studies have shown that 20-30 mg aspirin/d for pharmacokinetic reason selectively inhibit the thromboxane synthesis while the endogenous prostacyclin synthesis remains intact. Prostacyclin plays an important cardioprotective role for the ischemic heart, having antiplatelet and antifibrillatory effects, potentiates the antiplatelet effect of the nitrovasodilators and nitric oxide, and increases the release of adenosine. A superior preventive action and lower side effects of 30 mg/d aspirin in direct comparison with higher doses was first proved by the Cottbus reinfarction study. The 30 mg aspirin tablet per day ought to replace the present prevention with higher doses.
authors.affiliation: Instituts für Pharmakologie und Toxikologie, Martin-Luther-Universität Halle-Wittenberg, Halle.
authors.forename: W
authors.initials: W
authors.lastname: Förster
mesh_terms: D000818:Animals; D001241:Aspirin / Q000008:administration & dosage* / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D011464:Epoprostenol / Q000097:blood; D006801:Humans; D009203:Myocardial Infarction / Q000201:enzymology / Q000517:prevention & control*; D010974:Platelet Aggregation / Q000187:drug effects; D012008:Recurrence; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors
chemical_list: D011464:Epoprostenol; D013930:Thromboxane-A Synthase; D001241:Aspirin
vernacular_title: Reinfarktprophylaxe mit 100 mg oder 30 mg ASS täglich?